Bank of America
TRDA icon

Bank of America’s Entrada Therapeutics TRDA Stock Holding History

Bank of America’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$495K Sell
39,212
-26,767
-41% -$307K ﹤0.01% 4900
2025
Q4 		$678K Sell
65,979
-60,469
-48% -$510K ﹤0.01% 4740
2025
Q3 		$733K Buy
126,448
+89,975
+247% +$526K ﹤0.01% 5532
2025
Q2 		$245K Buy
36,473
+9,571
+36% +$77K ﹤0.01% 6086
2025
Q1 		$243K Sell
26,902
-8,819
-25% -$110K ﹤0.01% 6072
2024
Q4 		$618K Buy
35,721
+1,660
+5% +$30.1K ﹤0.01% 5385
2024
Q3 		$544K Buy
34,061
+5,131
+18% +$80.8K ﹤0.01% 5431
2024
Q2 		$412K Buy
28,930
+6,365
+28% +$90.5K ﹤0.01% 5462
2024
Q1 		$320K Sell
22,565
-4,865
-18% -$68.8K ﹤0.01% 5624
2023
Q4 		$414K Buy
27,430
+4,086
+18% +$60.5K ﹤0.01% 5623
2023
Q3 		$369K Buy
23,344
+1,526
+7% +$24K ﹤0.01% 5522
2023
Q2 		$330K Sell
21,818
-11,953
-35% -$165K ﹤0.01% 5525
2023
Q1 		$490K Buy
33,771
+28,475
+538% +$380K ﹤0.01% 5390
2022
Q4 		$71.6K Buy
5,296
+1,330
+34% +$23.3K ﹤0.01% 6363
2022
Q3 		$63K Sell
3,966
-9,025
-69% -$115K ﹤0.01% 6567
2022
Q2 		$158K Sell
12,991
-7,880
-38% -$59.8K ﹤0.01% 6247
2022
Q1 		$196K Sell
20,871
-1,971
-9% -$21.1K ﹤0.01% 6482
2021
Q4 		$391K Buy
+22,842
New +$554K ﹤0.01% 6067

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America's TRDA Position: Q1 2026 in Review

Bank of America reduced its Entrada Therapeutics (TRDA) stake by 41% in Q1 2026, selling an estimated $307K and leaving 39,212 shares worth $495K. The position accounts for ﹤0.01% of the portfolio, ranked #4900.

Bank of America first reported a position in TRDA in Q4 2021 and has held it in 18 quarters since. The position peaked at $733K in Q3 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Bank of America held 39,212 shares of Entrada Therapeutics worth $495K as of Q1 2026.
  • Bank of America sold 26,767 Entrada Therapeutics shares in Q1 2026, an estimated $307K.
  • Entrada Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4900 holding.
  • Bank of America first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Bank of America's Entrada Therapeutics position peaked at $733K in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.